CABA biotech catalysts & pipeline

CABALETTA BIO INC · Data as of 2026-09-08

Upcoming catalysts

resecabtagene autoleucel — Topline data

2H26

PC-free rese-cel data at higher doses from RESET-PV are anticipated in 2H26 and initial data at the lowest rese-cel dose from RESET-SLE™ are expected in 1H26 at the European Alliance of Associations for Rheumatology 2026 Congress, being held from June 3-6, 2026, in London, UK.

Source filing

resecabtagene autoleucel — NDA/BLA submission

next year

Pivotal RESET-Myositis ® cohort with outpatient dosing option progressing to support first planned BLA submission for rese-cel next year

Source filing

resecabtagene autoleucel — Topline data

mid-2027

Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel

Source filing

resecabtagene autoleucel — NDA/BLA submission

2H27

Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel

Source filing

Explore the free biotech catalyst calendar